TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05988320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pranayama breathing exercise
Description: Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through
Study: NCT04973345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: management of asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: management of asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: management of asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: management of asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: management of asthma symptoms
Study: NCT05750433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreforPro+B. subtilis DE111 probiotics
Description: PreforPro is bacteriophage-based product which was used in combination with Bacillus subtilis probiotics.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin is rice based powder which was used as placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B. subtilis DE111
Description: Bacillus subtilis probiotics.
Study: NCT04983797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTRELL Mapping Catheter
Description: Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).
Study: NCT04226976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otoband
Description: Participants with AUV will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: Participants with AUV will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
Study: NCT05610046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared sauna heating
Description: Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham sauna
Description: Participants will sit in an inactive infrared sauna at room temperature (21° Celsius) for a total of 40 minutes.
Study: NCT06334757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: 300 mg，IV，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar HLX04
Description: 7.5 mg/kg，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2，IV，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5，IV，Q3W
Study: NCT04784312

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 9MW1411 injection
Description: 9MW1411 injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 9MW1411 injection placebo
Description: 9MW1411 injection placebo
Study: NCT05418192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Environment
Description: Enriched Environment (EE) consisted of motor and sensory enriched play environment to promote participant's self-generated movements, exploration and task success. EE also included positioning in a graded manner. Visual stimulus and level appropriate vestibular stimulus was also given. Dosing of positioning and sensory inputs was done throughout the therapy. Primary Intervention will be given for 20 to 25 minutes intermittently for period of 4-5 hours a day, 5 days a week for 24 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Physcial Therapy
Description: Participants of this group received traditional physical therapy based NDT. No additional dosing guidance was given to this group. No home program was specifically assigned to this group. No specific environmental modifications were made for this group.
Study: NCT05387733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg CBL-514 per injection
Description: The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (2 mL each); total of 10 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (2 mL each); total of 20 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (2 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (2 mL each); total of 50 mg CBL-514.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg CBL-514 per injection
Description: The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (3 mL each); total of 15 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (3 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (3 mL each); total of 45 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (3 mL each); total of 75 mg CBL-514.
Study: NCT06297109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-specific implants
Description: Application of patient-specific implants for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mini-plates
Description: Application of conventional mini-plates for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
Study: NCT06151795

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: XTR006
Description: Single dose intravenous injection of XTR006. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
Study: NCT05986006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Disc Fusion (ACDF) Surgery w/ machined bone allograft
Description: Participant will undergo primary, elective one-level to four-level ACDF using machined bone allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Disc Fusion (ACDF) Surgery w/ Iliac Crest Bone Graft
Description: Participant will undergo primary, elective one-level to four-level ACDF using iliac crest bone allograft
Study: NCT05454631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical mask (5 different types)
Description: All the participants will wear 5 different types of surgical mask, in random order.
Study: NCT05837429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Volume High Intensity Exercise Training
Description: Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
Study: NCT05934929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA detection
Description: biological assessment on operating bed to detect residual circulating tumor DNA
Study: NCT06201585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
Description: SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
Study: NCT01154361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant (subcutaneous) and plazebo (intravenous)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)
Study: NCT06341205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection
Description: Dose administered will depend on randomisation and for experimental Arm on the risk of having undetectable rituximab level after 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiTUXimab Injection
Description: Dose administered will depend on randomisation and for experimental Arm on the risk of having undetectable rituximab level after 3 months
Study: NCT04533997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution plus intravenous furosemide
Description: Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide \> 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.4%, Na+ 135-145: 2.6%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous furosemide
Description: Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide \> 160 mg
Study: NCT05132829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 1 gram IV
Description: Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin and indomethacin
Description: Perioperative standard of care with cefazolin and indomethacin

Intervention type: DRUG
Group type: OTHER
Intervention: Cefazolin and indomethacin
Description: Perioperative standard of care with cefazolin and indomethacin
Study: NCT04726176

Intervention type: BIOLOGICAL
Intervention: Exposure to COVID-19
Description: To study the exposure of COVID-19 on the brain and executive functioning
Study: NCT04738344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention and Stent Implantation
Description: Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
Study: NCT05755971

Intervention type: OTHER
Group type: OTHER
Intervention: Combination taping
Description: Elastic and rigid tapes applied together for six weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination taping
Description: Elastic and rigid tapes applied together for six weeks
Study: NCT05644925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCSO Impulse System
Description: The PiCSO Impulse System is intended to reduce infarct size by intermittently occluding the coronary sinus outflow in patients undergoing a percutaneous coronary interventional procedure for myocardial infarction and presenting with Thrombolysis in myocardial infarction (TIMI) flow of 0 or 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Description: Minimally invasive procedures used to open clogged coronary arteries

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI)
Description: Minimally invasive procedures used to open clogged coronary arteries
Study: NCT06256523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: 0.5mg-13mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered the same volume as GZR18
Study: NCT06053294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CS+Fast
Description: (CS+): Flavored beverage solution with 110 calories of sucrose. Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CS+Slow
Description: (CS+): Flavored beverage solution with 110 calories of maltodextrin. Participants will consume flavored beverage solutions containing 110 calories of maltodexrin in 6 exposure sessions within 1 week.One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CS+Slow
Description: (CS+): Flavored beverage solution with 110 calories of maltodextrin. Participants will consume flavored beverage solutions containing 110 calories of maltodexrin in 6 exposure sessions within 1 week.One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CS+Slow
Description: (CS+): Flavored beverage solution with 110 calories of maltodextrin. Participants will consume flavored beverage solutions containing 110 calories of maltodexrin in 6 exposure sessions within 1 week.One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study: NCT03900767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record intervention
Description: AAC
Study: NCT05484336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage containing 8g spirulina
Description: Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage containing 8g spirulina
Description: Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage containing 8g spirulina
Description: Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT03900767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record intervention
Description: AAC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record intervention
Description: AAC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record intervention
Description: AAC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record intervention
Description: AAC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive standard Utah Quitline treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive standard Utah Quitline treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive standard Utah Quitline treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive standard Utah Quitline treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive phone calls
Study: NCT06159712

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Extra blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Extra blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Extra blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Extra blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Extra blood samples
Study: NCT06280573

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Wim Hoff method
Description: breathing exercises, cold exposure, and meditation
Study: NCT05765526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A novel electrolyzed water spray
Description: Study staff will use the novel electrolyzed water spray device and spray for approximately 10 minutes on the participant's scalp until half bottle (200ml) of water is used. Their scalp will then be rinsed and gently dried with a towel.
Study: NCT06374316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceiling-Mounted Air Purifiers
Description: The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Air Purifiers
Description: The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable or Ceiling Mounted Air Purifiers
Description: The Ceiling-Mounted and Portable devices will alternate weekly between being activated and deactivated in the three classrooms. Each classroom will also have three weeks with no purifier activated.This alternating pattern aims to assess the impact of the various air purifiers on air quality. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
Study: NCT04979338

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Continuous Infraclavicular Brachial Plexus Block
Description: 20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Continuous Femoral Nerve Block
Description: 20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Pudendal Nerve Block
Description: 20-40cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist, pre-incision\]
Study: NCT05579184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Ludotadipep
Description: Patients will receive 100 mCi of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (up to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection
Study: NCT05626907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet modification #1
Description: Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 130% of estimated daily caloric needs and for the other 7 days, meals will be low in calories, consistent with recommendations for weight loss.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet modification #2
Description: Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 150% of estimated daily caloric needs and for the other 7 days, meals will be meals will be low in calories, consistent with recommendations for weight loss.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet modification #3
Description: Participants will be provided all meals for a 14-day period to be approximately 100% of estimated daily caloric needs.
Study: NCT05360537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec / Liraglutide Injectable Product
Description: administration of Insulin Degludec/Liraglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administration of glargine insulin
Study: NCT04979338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% or 0.5% with or without 1:200K epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% or 0.5% with or without 1:200K epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% or 0.5% with or without 1:200K epinephrine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound guided Transversus Abdominis Plane Block
Description: 40-60cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist post-op or at end of surgery\]